Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studies
Authors:
- 1 March 2011
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 54 (4) , 807-811
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)Vascular Health and Risk Management, 2008
- Overview of Pharmacology and Clinical Trials Program with the Zotarolimus‐Eluting Endeavor StentJournal of Interventional Cardiology, 2006
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(-caprolactone) stent cuffBiomaterials, 2005
- Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer CellsClinical Cancer Research, 2004
- Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of RestenosisJournal of Medicinal Chemistry, 2004
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: Combination therapy for the futureAmerican Heart Journal, 2003
- Inflammation, Neointimal Hyperplasia, and RestenosisCirculation, 2003
- Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitroBiomaterials, 1999